Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Products under Development by Stage of Development | 8 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Products under Development by Therapy Area | 9 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Products under Development by Indication | 10 | 2 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Products under Development by Companies | 14 | 3 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Products under Development by Universities/Institutes | 17 | 2 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutics Assessment | 19 | 7 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Companies Involved in Therapeutics Development | 26 | 9 |
| Amgen Inc. | 26 | 1 |
| AnGes MG, Inc. | 27 | 1 |
| F-star Biotechnology Limited | 28 | 1 |
| Kringle Pharma, Inc. | 29 | 1 |
| M3 Biotechnology, Inc. | 30 | 1 |
| Minerva Biotechnologies Corporation | 31 | 1 |
| Molecular Partners AG | 32 | 1 |
| ViroMed Co., Ltd. | 33 | 1 |
| Yooyoung Pharmaceutical Co., Ltd. | 34 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drug Profiles | 35 | 22 |
| beperminogene perplasmid Drug Profile | 35 | 6 |
| FS-101 Drug Profile | 41 | 1 |
| Gene Therapy to Activate HGF for Myocardial Infarction Drug Profile | 42 | 1 |
| Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma Drug Profile | 43 | 1 |
| MM-201 Drug Profile | 44 | 1 |
| Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer Drug Profile | 45 | 1 |
| MP-0250 Drug Profile | 46 | 1 |
| NK-4 Drug Profile | 47 | 1 |
| rilotumumab Drug Profile | 48 | 2 |
| SL-186 Drug Profile | 50 | 1 |
| SL-188 Drug Profile | 51 | 1 |
| VM-202 Drug Profile | 52 | 4 |
| YYB-101 Drug Profile | 56 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Dormant Projects | 57 | 2 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Discontinued Products | 59 | 1 |
| Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Featured News &Press Releases | 60 | 12 |
| Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences | 60 | 1 |
| Sep 08, 2016: ViroMed proceeding with the World s first phase III gene therapy clinical trial for diabetic peripheral neuropathy | 60 | 1 |
| Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease | 61 | 1 |
| Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy | 61 | 1 |
| Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia | 62 | 1 |
| May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis | 63 | 1 |
| Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema | 64 | 1 |
| Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study | 64 | 1 |
| Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma | 65 | 1 |
| Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer | 66 | 1 |
| Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference | 67 | 1 |
| Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer | 68 | 1 |
| Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia | 69 | 1 |
| Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition | 69 | 2 |
| Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer | 71 | 1 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |
